Skip to main content
OpenTrials
Completed

NCT Number: NCT04693650

A Prospective, Multi-site, Randomized, Sham-Controlled, Double-Blind Trial With One-Way Crossover Designed to Assess the Effectiveness and Safety of the Gimer NeuroBlock SCS Trialing System for the Treatment of Chronic Back Pain and/or Lower Limb Pain

This study is a prospective, multi-site, randomized, shamcontrolled, double-blind trial with one-way crossover designed to assess the effectiveness and safety of the Gimer NeuroBlock SCS Trialing System for the treatment of chronic back pain and/or lower limb pain. The NeuroBlock SCS Trialing System is an ultra-high frequency SCS device for the treatment of patients with chronic back pain and/or lower limb pain who are refractory to conservative pain management. After screening procedures, eligible subjects will enter the study which is comprised of a 1-week randomized testing period, a 1-week follow-up period and 2-week observation period.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

China Medical University Hospital, Taichung, Taiwan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 20
  • Subject has been diagnosed with chronic, intractable pain of the trunk and/or limb(s) and is refractory to conservative therapy for a minimum of six months prior to the screening/baseline visit.
  • Subject has an average pain score of back or leg ≥ 5 or maximum pain score of back or leg ≥ 7 on the Visual Analogue Scale (VAS).
  • Subject is willing and able to comply with the procedure and requirements of this trial.
  • The subject is able to understand and provide informed consent, and has signed their written informed consent in accordance with IRB requirements.

Exclusion criteria

  • Subject has the following conditions by investigator's discretion at screening visit or during the last 3 months:
  • has the mental or psychological condition that affects pain perception or
  • has difficulty performing objective pain assessment or lack of suitability for participation in the study.
  • Subject has exhibited unstable pain condition within the past 28 days as interviewed by Investigator.
  • Subject has a currently diagnosed coagulation disorder, bleeding diathesis, progressive peripheral vascular disease with PLT < 100,000/μl or INR > 1.4 at screening visit.
  • Subject has unstable pain medication(s) for at least 28 days at investigator's discretion.
  • Subject currently has an active implantable device including ICD, pacemaker, spinal cord stimulator or intrathecal drug pump or subject requires magnetic resonance imaging (MRIs) or diathermy.
  • Subject has a current diagnosis of cancer with active symptoms.
  • Subject has a known terminal illness with life expectancy less than one year.
  • Subject has a systematic or local infection, which may increase study risk.
  • Subject currently has an indwelling device that may pose an increased risk of infection.
  • Subject is pregnant or breast feeding.
  • Subject has a medical history of drug or alcohol addiction within the past 2 years.
  • Subject has participation in any investigational study in the last 30 days or current enrollment in any trial.
  • Subject is currently involved in an injury claim law suit or medically related litigation, including workers compensation.
  • Subject is a prisoner.

Treatment and study plan

NeuroBlock UHF stimulation

Device

NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse

Other names: +RF (plus RF, pulsed RF)

Primary outcomes

  1. Effectiveness: Responder Rate

    Time frame: 2 weeks

    The responder rate of the test group and control group at the 2-week visit

  2. Safety: AEs and SAEs

    Time frame: 4 weeks

    Incidence of adverse events (AEs) and serious AEs (SAEs)

Sponsors and collaborators

Lead sponsor

GiMer Medical

Industry

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jan 5, 2021
Registry last updated
Feb 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.